Collegium Pharmaceutical (COLL) Share-based Compensation (2014 - 2026)

Collegium Pharmaceutical has reported Share-based Compensation for 13 years, with the latest figure at $9.9 million in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 87.05% year-over-year to $9.9 million in Q2 2026; TTM through Jun 2026 was $46.6 million, a 39.2% decrease from a year earlier, with the FY2025 full-year figure at $41.9 million, up 29.34% from the prior year.
• Share-based Compensation was $9.9 million for Q2 2026 at Collegium Pharmaceutical, down from $15.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $76.7 million in Q2 2025, with the low at $5.4 million in Q3 2022.
• Average Share-based Compensation over 5 years is $20.5 million, with a median of $8.7 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation surged 670.81% in 2024, then sank 87.05% in 2026.
• Over 5 years, Share-based Compensation stood at $5.7 million in 2022, then rose by 23.49% to $7.0 million in 2023, then grew by 8.48% to $7.6 million in 2024, then rose by 28.4% to $9.8 million in 2025, then gained by 1.83% to $9.9 million in 2026.
• The last three Share-based Compensation figures came in at $9.9 million (Q2 2026), $15.4 million (Q1 2026), and $9.8 million (Q4 2025), per Business Quant data.